$ATEX

Guttman-McCabe Christopher sold $7.5M of ATEX

Guttman-McCabe Christopher (Chief Reg & Comm Officer) sold 91,437 shares of Anterix Inc. (ATEX) at an average of $82.46 ($81.32–$84.29, $7.54M total) across 4 trades on 2026-06-15.

Original reporting
SEC EDGAR · Guttman-McCabe Christopher
Published Jun 17, 2026, 11:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 11:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ATEX
Bearish
medium confidence
Mentioned
$ATEX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATEXBearishLow
01

Why it matters

The newest disclosed fact is the officer’s open-market sale size (~$7.54M) and post-transaction holdings (77,807 shares).

02

Market read

Traders may note the insider selling signal, but it is unlikely to be a standalone driver of price without additional fundamental catalysts.

03

What to watch

Insider sales are more informative when paired with concurrent buying, guidance changes, or material operational/regulatory developments—none are present here.

Relevance 6/10Novelty 5/10Timing: Filed 2026-06-17; sale executed 2026-06-15.

Background

The article is an SEC Form 4 insider transaction disclosure for Anterix (ATEX).

Company-level read

Ticker impact

$ATEXBearishMedium confidence
Context

Anterix insider Form 4 shows officer Christopher Guttman-McCabe sold 91,437 shares in open-market trades for ~$7.54M.

Expected impact

Likely limited near-term impact; any reaction should be small unless accompanied by other news.

Evidence & confidence

The filing is a routine Form 4 open-market sale with no 10b5-1 plan stated; however, insider sales alone rarely drive sustained repricing without corroborating fundamentals.

Market effects

No clear sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

The sale could be for diversification, taxes, or pre-planned liquidity needs; absence of a stated 10b5-1 plan doesn’t prove bearish intent.

Key entities

  • Anterix Inc.

    Subject of the Form 4 insider sale disclosure.

  • Guttman-McCabe Christopher

    Chief Reg & Comm Officer who sold 91,437 shares across four trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ATEXMed

Is Anterix (ATEX) Quietly Reframing Its Connectivity Moat With New 900 MHz FCC Flexibility?

Anterix (ATEX) gained attention after the FCC approved expanded 900 MHz broadband use and granted it a license for satellite testing. This could broaden its network applications and reinforce its investment narrative, though profitability currently relies heavily on noncash spectrum gains. Analysts project $6.9M revenue and $935K earnings by 2028, with a potential 36% downside from current prices.

$ATEXMed

Anterix (ATEX) Q1 2027 Earnings Call Transcript

Anterix (ATEX) reported Q1 2027 revenue of $2M, up from $1.4M YoY, with net income of $240K. Operating expenses decreased to $12.9M. The company has $116M in cash, no debt, and $226.7M left for share repurchases. Management highlighted 12 active deals, spectrum clearing progress, and support for SpaceX's FCC proposal. CFO warned of potential higher costs if spectrum clearing is accelerated.

$ATEXMed

Anterix Inc. (ATEX): Results of Operations and Financial Condition

Anterix Inc. (ATEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Anterix Inc. Reports First Quarter Fiscal Year 2027 Results Woodland Park, NJ – August 11, 2026 – Anterix (NASDAQ: ATEX) today announced its first quarter fiscal 2027 results and filed its Form 10-Q for the three months ended June 30, 2026. Financial and Operational Highlights –

$ATEXMed

Anterix Inc. (ATEX): Results of Operations and Financial Condition

Anterix Inc. (ATEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 atex-20260331xpressrelease.htm EX-99.1 Document Anterix Inc. Reports Full Fiscal Year 2026 Results Woodland Park, NJ – June 10, 2026 – Anterix (NASDAQ: ATEX) today announced fiscal 2026 fourth quarter and full fiscal year financial results for the year ended March 31, 2